Tempest Therapeutics Q2 net loss $7.1M; cash $68.5M; appoints Ronit Simantov to board

Tempest Therapeutics, Inc.

2022-Q2 EPS reported -$17.30

Closed merger and $30M PIPE in June 2021; cash position $68.5M vs $18.8M at Dec 2020; runway extends into Q1’23.
Net loss $7.1M ($7.63 per share) vs $5.2M ($11.42) in Q2 2020; six-month net loss $12.4M ($17.30).
TPST-1120 selected 600mg BID RP2D; observed deep confirmed partial response in combination with nivolumab in RCC.
Appointed Ronit Simantov, M.D. as Class III director effective Aug 6, 2021; granted option for 6,635 shares.
TREX-1 inhibitor advanced to picomolar IC50 potency; in vivo efficacy shown in mouse tumor model.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ronit Simantov

Class III director

TPST · Tempest Therapeutics, Inc.

Effective: 2021-08-06
Filed: August 12, 2021, 7:59 PM ET

Effective as of August 6, 2021, the Company’s Board of Directors (the “Board”) appointed Ronit Simantov, M.D. to serve as Class III director of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ronit Simantov was appointed as Class III director at Tempest Therapeutics, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

Effective as of August 6, 2021, the Company’s Board of Directors (the “Board”) appointed Ronit Simantov, M.D. to serve as Class III director of the Board.

View on SEC.gov

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-244725

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.